Completed
PHASE2
INTERVENTIONAL
NCT02453711
Investigation of Safety and Efficacy of Once-daily Semaglutide in Obese Subjects Without Diabetes Mellitus
View on ClinicalTrials.gov
Updated Dec 15, 2025
Brief Summary
This trial is conducted globally. The aim of this trial is to investigate safety and efficacy of once-daily semaglutide in obese subjects without diabetes mellitus.
Interventions
Name:
semaglutide
Type:
DRUG
Description:
Once-daily subcutaneous (s.c., under the skin) administration with dose escalation.
Name:
liraglutide
Type:
DRUG
Description:
Once-daily subcutaneous (s.c., under the skin) administration with dose escalation.
Name:
placebo
Type:
DRUG
Description:
Once-daily subcutaneous (s.c., under the skin) administration.
Primary Outcomes
Measure:
Relative Change in Body Weight (%)
TimeFrame:
Week 0, Week 52
Description:
Relative change from baseline (week 0) in body weight was evaluated at week 52. Analysis of in-trial data with missing observations imputed from the pooled placebo arms based on a jump to reference multiple (x1000) imputation (J2R-MI) approach. Week 52 responses were analysed using an analysis of covariance model with treatment, region and sex as factors and baseline body weight as covariate. In-trial observation period was defined as the period from randomisation to last contact with trial site.
Trial Information
NCT ID
NCT02453711
Status
Completed
Study Type
INTERVENTIONAL
Phases
PHASE2
Sponsor
Novo Nordisk A/S
Last Updated
December 15, 2025